
Pulmonary Arterial Hypertension - Pipeline Insight, 2024
Description
Pulmonary Arterial Hypertension - Pipeline Insight, 2024
DelveInsight’s, “Pulmonary Arterial Hypertension - Pipeline Insight, 2024,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pulmonary Arterial Hypertension: Overview
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test”, which measures how far an individual can walk in that time period. Treatment for PAH includes prostaglandins, endothelin receptor antagonists, phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies.
""Pulmonary Arterial Hypertension - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Arterial Hypertension pipeline landscape is provided which includes the disease overview and Pulmonary Arterial Hypertension treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Arterial Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Arterial Hypertension.
This segment of the Pulmonary Arterial Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Arterial Hypertension Emerging Drugs
- Sotatercept: Acceleron Pharma
- LIQ861: Liquidia Technologies
Further product details are provided in the report……..
Pulmonary Arterial Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Arterial Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pulmonary Arterial Hypertension
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pulmonary Arterial Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Arterial Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Arterial Hypertension drugs.
Pulmonary Arterial Hypertension Report Insights
- Pulmonary Arterial Hypertension Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pulmonary Arterial Hypertension drugs?
- How many Pulmonary Arterial Hypertension drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Arterial Hypertension?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck Sharp & Dohme
- Acceleron Pharma
- Liquidia Technologies
- Gossamer Bio
- Resverlogix
- PhaseBio Pharmaceuticals
- Pharmosa BioPharm
- Complexa
- Gmax Biopharm Australia
- Mezzion
- Radikal Therapeutics
- Galectin Therapeutics
- Altavant Sciences
- Ribomic
- MK-5475
- Sotatercept
- LIQ861
- GB-002
- Apabetalone
- PB1046
- L-606
- CXA-10
- GMA-301
- Udenafil
- R107
- Belapectin
- Rodatristat ethyl
- RBM-011
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Pulmonary Arterial Hypertension: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Sotatercept: Acceleron Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- GB-002: Gossamer Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Apabetalone: Resverlogix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- Comparative Analysis
- R107: Radikal Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pulmonary Arterial Hypertension Key Companies
- Pulmonary Arterial Hypertension Key Products
- Pulmonary Arterial Hypertension- Unmet Needs
- Pulmonary Arterial Hypertension- Market Drivers and Barriers
- Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
- Pulmonary Arterial Hypertension Analyst Views
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.